Switch theme
Sign up to access all valuation multiples
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
2004
2.0K+
LTM Revenue $728M
LTM EBITDA $278M
$1.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Amphastar Pharma has a last 12-month revenue (LTM) of $728M and a last 12-month EBITDA of $278M.
In the most recent fiscal year, Amphastar Pharma achieved revenue of $732M and an EBITDA of $277M.
Amphastar Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Amphastar Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $728M | XXX | $732M | XXX | XXX | XXX |
| Gross Profit | $398M | XXX | $374M | XXX | XXX | XXX |
| Gross Margin | 55% | XXX | 51% | XXX | XXX | XXX |
| EBITDA | $278M | XXX | $277M | XXX | XXX | XXX |
| EBITDA Margin | 38% | XXX | 38% | XXX | XXX | XXX |
| EBIT | $238M | XXX | $205M | XXX | XXX | XXX |
| EBIT Margin | 33% | XXX | 28% | XXX | XXX | XXX |
| Net Profit | $184M | XXX | $160M | XXX | XXX | XXX |
| Net Margin | 25% | XXX | 22% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $450M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Amphastar Pharma's stock price is $26.
Amphastar Pharma has current market cap of $1.2B, and EV of $1.6B.
See Amphastar Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.6B | $1.2B | XXX | XXX | XXX | XXX | $3.55 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Amphastar Pharma has market cap of $1.2B and EV of $1.6B.
Amphastar Pharma's trades at 2.2x EV/Revenue multiple, and 5.9x EV/EBITDA.
Equity research analysts estimate Amphastar Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Amphastar Pharma has a P/E ratio of 6.6x.
See valuation multiples for Amphastar Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV (current) | $1.6B | XXX | $1.6B | XXX | XXX | XXX |
| EV/Revenue | 2.2x | XXX | 2.2x | XXX | XXX | XXX |
| EV/EBITDA | 5.8x | XXX | 5.9x | XXX | XXX | XXX |
| EV/EBIT | 6.8x | XXX | 7.9x | XXX | XXX | XXX |
| EV/Gross Profit | 4.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 6.6x | XXX | 7.6x | XXX | XXX | XXX |
| EV/FCF | 11.5x | XXX | 9.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAmphastar Pharma's last 12 month revenue growth is 1%
Amphastar Pharma's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.
Amphastar Pharma's rule of 40 is 39% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Amphastar Pharma's rule of X is 42% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Amphastar Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1% | XXX | 2% | XXX | XXX | XXX |
| EBITDA Margin | 38% | XXX | 38% | XXX | XXX | XXX |
| EBITDA Growth | -7% | XXX | 2% | XXX | XXX | XXX |
| Rule of 40 | 39% | XXX | 39% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 42% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 10% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 23% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Amphastar Pharma acquired XXX companies to date.
Last acquisition by Amphastar Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Amphastar Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Amphastar Pharma founded? | Amphastar Pharma was founded in 2004. |
| Where is Amphastar Pharma headquartered? | Amphastar Pharma is headquartered in United States of America. |
| How many employees does Amphastar Pharma have? | As of today, Amphastar Pharma has 2.0K+ employees. |
| Who is the CEO of Amphastar Pharma? | Amphastar Pharma's CEO is Dr. Jack Yongfeng Zhang, PhD. |
| Is Amphastar Pharma publicy listed? | Yes, Amphastar Pharma is a public company listed on NAS. |
| What is the stock symbol of Amphastar Pharma? | Amphastar Pharma trades under AMPH ticker. |
| When did Amphastar Pharma go public? | Amphastar Pharma went public in 2014. |
| Who are competitors of Amphastar Pharma? | Similar companies to Amphastar Pharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Amphastar Pharma? | Amphastar Pharma's current market cap is $1.2B |
| What is the current revenue of Amphastar Pharma? | Amphastar Pharma's last 12 months revenue is $728M. |
| What is the current revenue growth of Amphastar Pharma? | Amphastar Pharma revenue growth (NTM/LTM) is 1%. |
| What is the current EV/Revenue multiple of Amphastar Pharma? | Current revenue multiple of Amphastar Pharma is 2.2x. |
| Is Amphastar Pharma profitable? | Yes, Amphastar Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Amphastar Pharma? | Amphastar Pharma's last 12 months EBITDA is $278M. |
| What is Amphastar Pharma's EBITDA margin? | Amphastar Pharma's last 12 months EBITDA margin is 38%. |
| What is the current EV/EBITDA multiple of Amphastar Pharma? | Current EBITDA multiple of Amphastar Pharma is 5.8x. |
| What is the current FCF of Amphastar Pharma? | Amphastar Pharma's last 12 months FCF is $142M. |
| What is Amphastar Pharma's FCF margin? | Amphastar Pharma's last 12 months FCF margin is 20%. |
| What is the current EV/FCF multiple of Amphastar Pharma? | Current FCF multiple of Amphastar Pharma is 11.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
